Active, not recruitingPHASE1, PHASE2NCT02599922

Safety and Efficacy Trial of AAV Gene Therapy in Patients With CNGB3 Achromatopsia (A Clarity Clinical Trial)

Studying Achromatopsia

Last synced from ClinicalTrials.gov May 6, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Beacon Therapeutics
Principal Investigator: David Jacobs, MD, MBA
Applied Genetic Technologies Corporation
Intervention: rAAV2tYF-PR1.7-hCNGB3(biological)
Enrollment: 32 enrolled
Eligibility: 4 years · All sexes
Timeline: 2016 – 2026

Study locations (8)

VitreoRetinal Associates, Gainesville, Florida, United States
Bascom Palmer Eye Institute, Miami, Florida, United States
Pangere Center for Inherited Retinal Diseases, The Chicago Lighthouse for People Who Are Blind or Visually Imp, Chicago, Illinois, United States
Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, United States
Boston Children's Hospital, Boston, Massachusetts, United States
Duke Eye Center, Duke University Medical Center, Durham, North Carolina, United States
Cincinnati Eye Institute, Cincinnati, Ohio, United States
Casey Eye Institute, Oregon Health and Sciences University, Portland, Oregon, United States

Collaborators

National Eye Institute (NEI)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02599922 on ClinicalTrials.gov

Other trials for Achromatopsia

Additional recruiting or active studies for the same condition.

See all trials for Achromatopsia →

← Back to all trials